Public-domain · open source
OpenJurist
← 920 F.2d 984 - Abbott Laboratories v. Young

Abbott Laboratories v. Young’s Empirical Analysis

920 F.2d 984 · 1990

Citation profile

74
cited by 74 later decisions
5
states following
January 2023
most recently cited

28 federal appellate · 24 district · 5 state decisions

How this case has been cited

Cited by 74 later decisions — most recently January 2023 · most notably State v. Thomas (2001), National Mining Ass'n v. U.S. Army Corps of Engineers (1998)

28 federal appellate · 24 district · 5 state decisions

2601990200020102020decided

Later decisions citing this case, by decade. The current decade is in progress, and our corpus holds fewer opinions from the most recent years, so the latest bars are undercounted — not a real decline.

Relationships

Applies 21 U.S.C. § 355 (Federal Food, Drug, and Cosmetic Act)

Relies on Chevron U. S. A. Inc. v. Natural Resources Defense Council, Inc. · Motor Vehicle Manufacturers Association of United States Inc v. State Farm Mutual Automobile Insurance Company Consumer Alert · Immigration & Naturalization Service v. Cardoza-Fonseca · Consumer Product Safety Commission v. GTE Sylvania, Inc. · Mart Corporation v. Cartier Inc 47th Street Photo Inc

Most-quoted passages

The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 74 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.

  1. “[I]t is not impermissible under Chevron for an agency to interpret [the same] imprecise term differently in two separate sections of a statute which have different purposes.”
    4 later decisions quote this exact passage · from the majority
  2. “[t]he `reasonableness' of an agency's construction depends on the construction's `fit' with the statutory language as well as its conformity to statutory purposes.”
    4 later decisions quote this exact passage · from the majority
  3. “two conflicting policy objectives: to induce name-brand pharmaceutical firms to make the investments necessary to research and develop new drug products, while simultaneously enabling competitors to bring cheaper, generic copies of those drugs to market.”
    3 later decisions quote this exact passage · from the dissent

How this case has been treated — in progress

Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.